CVM
LSTA icon

Cheviot Value Management’s Lisata Therapeutics LSTA Stock Holding History

Cheviot Value Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15 Hold
3
– – ﹤0.01% 423
2025
Q4 		$14 Hold
3
– – ﹤0.01% 414
2025
Q3 		$8 Hold
3
– – ﹤0.01% 442
2025
Q2 		$8 Hold
3
– – ﹤0.01% 431
2025
Q1 		$7 Buy
+3
New +$8 ﹤0.01% 453

Other funds holding LSTA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Cheviot Value Management's LSTA Position: Q1 2026 in Review

Cheviot Value Management held its Lisata Therapeutics (LSTA) position steady in Q1 2026 at 3 shares worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #423.

Cheviot Value Management first reported a position in LSTA in Q1 2025 and has held it in 5 quarters since. 34 funds tracked by Wall St. Rank hold LSTA as of Q1 2026.

  • Cheviot Value Management held 3 shares of Lisata Therapeutics worth $15 as of Q1 2026.
  • Cheviot Value Management left its Lisata Therapeutics share count unchanged in Q1 2026.
  • Lisata Therapeutics made up ﹤0.01% of Cheviot Value Management's portfolio in Q1 2026, its #423 holding.
  • Cheviot Value Management first reported a position in Lisata Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2026.

Based on Cheviot Value Management's 13F filing for Q1 2026, filed 12 May 2026.